About
Ocular AAV gene therapy company. Lead programs ATSN-101 for GUCY2D-associated LCA1 (12-month Phase 1/2 data published in The Lancet, Sep 2024) and ATSN-201 for X-linked retinoschisis. RMAT designation held.
HQ: Durham, NC, USA
Funding
$150M Series C (Apr 2025, Bain Capital Life Sciences-led)
Total raised ~$175M–$238M depending on source.